On Nov 15, major Wall Street analysts update their ratings for $bluebird bio (BLUE.US)$, with price targets ranging from $0.5 to $2.
J.P. Morgan analyst Eric Joseph downgrades to a sell rating.
BofA Securities analyst Jason Gerberry downgrades to a hold rating, and adjusts the target price from $3 to $0.5.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $4 to $2.
William Blair analyst Sami Corwin maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $bluebird bio (BLUE.US)$'s main analysts recently are as follows:
Revenue performance for Bluebird Bio in Q3 did not meet expectations, influenced by the scheduling of infusions, as noted by an analyst.
Bluebird Bio's recent quarterly report showed a miss on sales and a significant shortening of its cash runway projection, now expected to reach into the first quarter of 2025, as opposed to the second quarter. Additionally, a recent proxy vote did not secure enough votes to authorize a reverse stock split and an increased allocation for share issuance, effectively eliminating equity financing as an option to raise capital. This development leaves limited options for the company to continue operating.
Here are the latest investment ratings and price targets for $bluebird bio (BLUE.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
